Browse Penn-owned technologies available for licensing.
Neuroendocrine tumors (NETs) pose serious threats to patients’ well-being as malignant diseases, and most patients with metastatic NETs succumb to the disease. Using Sequential Tumor-related Antibody and antigen Retrieving (STAR) technology Dr. Xianxin Hua, MD, PhD at the University of Pennsylvania Medical School and his team have identified unique nanobodies which are being tested for their ability to eliminate neuroendocrine tumors in an animal model.
Stage of Development:
Being validated in animal model to successfully target CAR-T cells to the tumor cells, and for switchable CAR-T
Docket # 18-8498-02